67023-52-3

Upstream product

• 87-42-3 6-chloropurine 
• 140-75-0 para-fluorobenzylamine 
• 87-42-3 6-chloro-7H-purine 

Downstream Products

• 886451-54-3 [Co(6-(4-fluorobenzylamino)purinium)Cl(H₂O)2]*H₂O 

Relevant academic research and scientific papers

Spezific Interaction of Cytokinins and Their Analogs with Rotenone-sensitive Internal NADH Dehydrogenase in Potato Tuber Mitochondria

Effects of cytokinins were studied on rotenone-sensitive NADH dehydrogenase in mitochondria from fresh potato tubers (Solanum tuberosum), in consideration of the operation of external and rotenone-insensitive internal NADH dehydrogenases that has not been

Design, synthesis and ability of non-gold complexed substituted purine derivatives to inhibit LPS-induced inflammatory response

In order to study the anti-inflammatory activity of novel 6-substituted and 6,9-disubstituted purine derivatives, 20 compounds, L1–10 and W1–10, derived from purine and lacking a gold complex were designed, synthesized and their anti-inflammatory activity was screened. LPS-induced TNF-α, IL-1β, IL-6, PGE2, NO, COX-2 and iNOS mRNA were evaluated, and western blot and NF-κB p65 translocation assay were performed in RAW 264.7 macrophages. Furthermore, carrageenan-induced hind paw edema experiments were performed in mice. Compound L1, L4, W2, and W4 markedly exerted a dose-dependent inhibition of TNF-α, IL-1β, IL-6 and PGE2 release induced by LPS in RAW 264.7 macrophages. Moreover, these compounds strongly inhibited LPS-induced NO, COX-2 and iNOS mRNA in the same cells. Anti-inflammatory activity tests in vivo showed that L1 and L4 were more effective than Au(L3)(PPh3), a known anti-inflammatory agent, at 2–5 h, and W4 was the most effective at 3–5 h after dosing. Thus, W2, W4, and L1, L4, could effectively inhibit LPS-induced inflammatory response in vitro and in vivo suggesting a promising role as anti-inflammatory agents.

6-substituted-9H-purine derivative and preparation method and application thereof

The invention discloses a 6-substituted-9H-purine derivative and a preparation method and application thereof. The derivative has the structure shown as the formula (I). In the formula (I), R is selected from one of pyrrolidiny, furan-2-methyl, benzenesulfonyl, and substituted or unsubstituted phenyl or benzyl, wherein a substituent on phenyl or benzyl is independently selected from one or more of C1-C4 alkoxy, C1-C4 alkyl, hydroxyl, halogen and a group shown in the description, and R4 is independently selected from H or alkyl-substituted benzyl. It is shown in the experimental results that compared with 6-benzyl purine compound complex gold ions (an inhibitor 3), the 6-substituted-9H-purine derivative is higher in inhibition ratio of inflammatory factors and has better anti-inflammatory activity. The 6-substituted-9H-purine derivative has the potential as an anti-inflammatory medicine.

9-subsituted-N-(2-chlorobenzyl)purine-6-amine derivative, as well as preparation method and application thereof

The invention discloses a 9-subsituted-N-(2-chlorobenzyl)purine-6-amine derivative. The structure of the derivative is shown in a formula (I), where R is selected from a hydrogen atom, a C1-C4 alkyl group and a substituted or unsubstituted benzyl group, and a substituent on the benzyl group is one or more independently selected from halogen, -CF3, a C1-C4 alkoxy group, a C1-C4 alkyl group and a nitro group; R4 is a substituted or unsubstituted phenyl group or benzyl group, and a substituent on the phenyl group or the benzyl group is one or more of halogen and a methoxy group. Compared with a 6-benyl adenine compound complex gold ion (inhibitor 3), the 9-subsituted-N-(2-chlorobenzyl)purine-6-amine derivative is proved by testing results to have the advantages of higher inflammation factor inhibition rate, higher anti-inflammation activity and potential for use as an anti-inflammation medicament. (The formula (I) is shown in the description.).

Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)

The present invention relates to a method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome X, metabolic syndrome and obesity.

Preparation and biological activity of 6-benzylaminopurine derivatives in plants and human cancer cells

To study the structure-activity relationships of aromatic cytokinins, the cytokinin activity at both the receptor and cellular levels, as well as CDK inhibitory and anticancer properties of 38 6-benzylaminopurine (BAP) derivatives were compared in various